Nonequivalence of Inhaled and Nebulized Salbutamol in the Assessment of Endothelial Dysfunction

Roy L. Soiza, M. Yaqoob Bhat, Mike A. Crilly, David J. P. Williams

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A noninvasive measure of global endothelial dysfunction may be obtained by pulse wave analysis (PWA) before and after administration of inhaled salbutamol. As some subjects may have difficulty using an inhaler, we determined whether equivalent doses of inhaled and nebulized salbutamol produced similar effects on a key measure obtained from PWA-the augmentation index (AIx). Twenty volunteers (11 with vascular risk factors and 9 healthy controls) underwent PWA at the right radial artery using SphygmoCor. Subjects were randomized to receive either 400 mu g inhaled salbutamol via spacer device or 2.5 mg nebulized salbutamol. PWA was performed until there was no further drop in AIx. After AIx returned to baseline, salbutamol was administered via the alternative route and measurements were repeated. The primary outcome was the intraclass correlation coefficient of agreement (ICC) between maximum change in AIx following inhaled and nebulized salbutamol. The ICC was 0.32 (95% CI -0.07 to 0.64) and 0.39 (95% CI -0.04 to 0.70) with and without correction for heart rate. The median maximum decrease in AIx after inhaler was 4.8% (IQR 1.8-7.1), and after nebulizer was 8.5% (IQR 7.5-11.4) (p = <.001). When corrected for heart rate, the median maximum fall in AIx after inhaler was 4.0% (IQR 2.0-7.9) and after nebulized salbutamol was 5.0% (IQR 3.8-9.6) (p = 0.24). Although inhaled and nebulized salbutamol produced similar median reductions in AIx, the correlation between the two methods of salbutamol delivery was weak. Further research is required to validate the fall in AIx after nebulized salbutamol as a measure of endothelial dysfunction.

Original languageEnglish
Pages (from-to)262-268
Number of pages7
JournalCardiovascular Therapeutics
Volume26
Issue number4
Early online date11 Nov 2008
DOIs
Publication statusPublished - 2008

Keywords

  • artery
  • endothelial function
  • endothelium
  • nitric oxide
  • pulse wave analysis
  • salbutamol
  • pulse-wave analysis
  • arterial stiffness
  • augmentation index
  • lung delivery
  • obese women
  • pressure
  • hypertension
  • humans
  • form

Cite this

Nonequivalence of Inhaled and Nebulized Salbutamol in the Assessment of Endothelial Dysfunction. / Soiza, Roy L.; Bhat, M. Yaqoob; Crilly, Mike A.; Williams, David J. P.

In: Cardiovascular Therapeutics, Vol. 26, No. 4, 2008, p. 262-268.

Research output: Contribution to journalArticle

@article{99b2db141a144ce69e522dce4ae891da,
title = "Nonequivalence of Inhaled and Nebulized Salbutamol in the Assessment of Endothelial Dysfunction",
abstract = "A noninvasive measure of global endothelial dysfunction may be obtained by pulse wave analysis (PWA) before and after administration of inhaled salbutamol. As some subjects may have difficulty using an inhaler, we determined whether equivalent doses of inhaled and nebulized salbutamol produced similar effects on a key measure obtained from PWA-the augmentation index (AIx). Twenty volunteers (11 with vascular risk factors and 9 healthy controls) underwent PWA at the right radial artery using SphygmoCor. Subjects were randomized to receive either 400 mu g inhaled salbutamol via spacer device or 2.5 mg nebulized salbutamol. PWA was performed until there was no further drop in AIx. After AIx returned to baseline, salbutamol was administered via the alternative route and measurements were repeated. The primary outcome was the intraclass correlation coefficient of agreement (ICC) between maximum change in AIx following inhaled and nebulized salbutamol. The ICC was 0.32 (95{\%} CI -0.07 to 0.64) and 0.39 (95{\%} CI -0.04 to 0.70) with and without correction for heart rate. The median maximum decrease in AIx after inhaler was 4.8{\%} (IQR 1.8-7.1), and after nebulizer was 8.5{\%} (IQR 7.5-11.4) (p = <.001). When corrected for heart rate, the median maximum fall in AIx after inhaler was 4.0{\%} (IQR 2.0-7.9) and after nebulized salbutamol was 5.0{\%} (IQR 3.8-9.6) (p = 0.24). Although inhaled and nebulized salbutamol produced similar median reductions in AIx, the correlation between the two methods of salbutamol delivery was weak. Further research is required to validate the fall in AIx after nebulized salbutamol as a measure of endothelial dysfunction.",
keywords = "artery, endothelial function, endothelium, nitric oxide, pulse wave analysis, salbutamol, pulse-wave analysis, arterial stiffness, augmentation index, lung delivery, obese women, pressure, hypertension, humans, form",
author = "Soiza, {Roy L.} and Bhat, {M. Yaqoob} and Crilly, {Mike A.} and Williams, {David J. P.}",
year = "2008",
doi = "10.1111/j.1755-5922.2008.00063.x",
language = "English",
volume = "26",
pages = "262--268",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Nonequivalence of Inhaled and Nebulized Salbutamol in the Assessment of Endothelial Dysfunction

AU - Soiza, Roy L.

AU - Bhat, M. Yaqoob

AU - Crilly, Mike A.

AU - Williams, David J. P.

PY - 2008

Y1 - 2008

N2 - A noninvasive measure of global endothelial dysfunction may be obtained by pulse wave analysis (PWA) before and after administration of inhaled salbutamol. As some subjects may have difficulty using an inhaler, we determined whether equivalent doses of inhaled and nebulized salbutamol produced similar effects on a key measure obtained from PWA-the augmentation index (AIx). Twenty volunteers (11 with vascular risk factors and 9 healthy controls) underwent PWA at the right radial artery using SphygmoCor. Subjects were randomized to receive either 400 mu g inhaled salbutamol via spacer device or 2.5 mg nebulized salbutamol. PWA was performed until there was no further drop in AIx. After AIx returned to baseline, salbutamol was administered via the alternative route and measurements were repeated. The primary outcome was the intraclass correlation coefficient of agreement (ICC) between maximum change in AIx following inhaled and nebulized salbutamol. The ICC was 0.32 (95% CI -0.07 to 0.64) and 0.39 (95% CI -0.04 to 0.70) with and without correction for heart rate. The median maximum decrease in AIx after inhaler was 4.8% (IQR 1.8-7.1), and after nebulizer was 8.5% (IQR 7.5-11.4) (p = <.001). When corrected for heart rate, the median maximum fall in AIx after inhaler was 4.0% (IQR 2.0-7.9) and after nebulized salbutamol was 5.0% (IQR 3.8-9.6) (p = 0.24). Although inhaled and nebulized salbutamol produced similar median reductions in AIx, the correlation between the two methods of salbutamol delivery was weak. Further research is required to validate the fall in AIx after nebulized salbutamol as a measure of endothelial dysfunction.

AB - A noninvasive measure of global endothelial dysfunction may be obtained by pulse wave analysis (PWA) before and after administration of inhaled salbutamol. As some subjects may have difficulty using an inhaler, we determined whether equivalent doses of inhaled and nebulized salbutamol produced similar effects on a key measure obtained from PWA-the augmentation index (AIx). Twenty volunteers (11 with vascular risk factors and 9 healthy controls) underwent PWA at the right radial artery using SphygmoCor. Subjects were randomized to receive either 400 mu g inhaled salbutamol via spacer device or 2.5 mg nebulized salbutamol. PWA was performed until there was no further drop in AIx. After AIx returned to baseline, salbutamol was administered via the alternative route and measurements were repeated. The primary outcome was the intraclass correlation coefficient of agreement (ICC) between maximum change in AIx following inhaled and nebulized salbutamol. The ICC was 0.32 (95% CI -0.07 to 0.64) and 0.39 (95% CI -0.04 to 0.70) with and without correction for heart rate. The median maximum decrease in AIx after inhaler was 4.8% (IQR 1.8-7.1), and after nebulizer was 8.5% (IQR 7.5-11.4) (p = <.001). When corrected for heart rate, the median maximum fall in AIx after inhaler was 4.0% (IQR 2.0-7.9) and after nebulized salbutamol was 5.0% (IQR 3.8-9.6) (p = 0.24). Although inhaled and nebulized salbutamol produced similar median reductions in AIx, the correlation between the two methods of salbutamol delivery was weak. Further research is required to validate the fall in AIx after nebulized salbutamol as a measure of endothelial dysfunction.

KW - artery

KW - endothelial function

KW - endothelium

KW - nitric oxide

KW - pulse wave analysis

KW - salbutamol

KW - pulse-wave analysis

KW - arterial stiffness

KW - augmentation index

KW - lung delivery

KW - obese women

KW - pressure

KW - hypertension

KW - humans

KW - form

U2 - 10.1111/j.1755-5922.2008.00063.x

DO - 10.1111/j.1755-5922.2008.00063.x

M3 - Article

VL - 26

SP - 262

EP - 268

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 4

ER -